Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Patient Factors, Safety, and Long-Term Efficacy Best Inform Treatment Selection Across Hematologic Malignancies

January 22nd 2024

Michael Choi, MD, expands on significant advancements and treatment considerations in hematologic malignancies.

Olverembatinib Added to NCCN Guidelines for CML

January 22nd 2024

Olverembatinib has been added to the NCCN's latest 2024 guidelines for management of chronic myeloid leukemia.

Dr McCloskey on Flow Cytometry and Machine Learning in Hematologic Malignancy Diagnosis

January 20th 2024

James K. McCloskey, MD, discusses the potential for machine learning to replace flow cytometry analyses in patients with hematologic neoplasms.

Transplant Complications and Survival Outcomes

January 19th 2024

Analyze risks and complications associated with allo-HSCT, including graft-versus-host disease, infections, relapse, and regimen-related toxicities.

Supportive Care Measures for Patients Planning to Receive an Allogenic Transplant

January 19th 2024

This presentation will detail the supportive therapies and interventions provided to patients before, during, and after undergoing allo-HSCT. The speaker will also discuss management of treatment side effects and comorbidities to optimize patient outcomes.

Hematologic Malignancies and Transplant Options and Conditioning Regimens Used in Allo-HSCT

January 19th 2024

Delve into the pre-transplant conditioning regimens such as chemotherapy and radiation used to prepare and immunosuppress patients to prevent graft rejection prior to allogeneic hematopoietic stem cell transplantation.

FDA Grants Orphan Drug Designation to PTX-252 for AML

January 19th 2024

The FDA has granted an orphan drug designation to PTX-252 for the treatment of patients with acute myeloid leukemia.

MAJIC-PV: Clinical Implications in PV

January 19th 2024

Experts discuss the clinical implications of the MAJIC-PV trial.

Polycythemia Vera: Choosing the Right Treatment

January 19th 2024

Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.

Expectations of Chronic GVHD Treatment

January 18th 2024

The panel reviews recent developments in treatments, therapeutic approaches post-transplant, and the importance of clear communication in navigating patient expectations.

Monitoring Patients with GVHD

January 18th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss challenges in detecting and diagnosing chronic GVHD. The panel advocates for vigilant communication, early detection, and ongoing patient education for comprehensive post-transplant care.

Dr Phillips on Ongoing Research to Address Unmet Needs in Patients With High-Risk MCL

January 17th 2024

Tycel Phillips, MD, discusses the potential advantages of treating patients with relapsed/refractory mantle cell lymphoma in the phase 3 GLOBRYTE trial.

Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL

January 16th 2024

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Zanubrutinib as Third-Line and Beyond Therapy for FL

January 16th 2024

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

State of the Science Summit - Hematologic Malignancies: Chaired by Jennifer Amengual, MD

January 16th 2024

State of the Science Summit - Hematologic Malignancies: Chaired by Jennifer Amengual, MD

Tafasitamab and Lenalidomide for R/R DLBCL

January 16th 2024

A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.

Treatment Selection in Second Line R/R DLBCL

January 16th 2024

Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.

Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL

January 16th 2024

A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.

Polycythemia Vera: Treatment Goals and Options

January 12th 2024

Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.

REVEAL Study: Clinical Implications

January 12th 2024

Expert oncologists discuss the REVEAL study and provide their thoughts on these data and the impact in clinical practice.